-
Rituximab, sold
under the
brand name
Rituxan among others, is a
monoclonal antibody medication used to
treat certain autoimmune diseases and
types of...
- of t-FL (e.g. the
addition to
standard chemotherapy of
agents such as
rituximab) have
improved overall survival times.
These newer regimens may also delay...
-
patients who
cannot use corticosteroids. The anti-CD20
monoclonal antibody rituximab has been
found to be
effective in
treating some
otherwise refractory cases...
-
antibodies such as
rituximab,
which are
increasingly being used as first-line treatment. In
summer 2018, the FDA
granted full
approval to
rituximab for this application...
- anti-CD20
monoclonal antibody rituximab (Rituxan, Mabthera) it is
called R-DHAP or DHAP-R. [R]-DHAP
regimen consists of:
Rituximab, a
monoclonal antibody, directed...
-
methotrexate for
moderate to
severe rheumatoid arthritis. The
biologic agent rituximab (anti-B cell therapy) is now
licensed for use in
refractory rheumatoid...
- corticosteroids.
Sometimes the
chimeric anti-CD20
monoclonal antibody,
rituximab, is
added to this
treatment regimen to form the R-CHOP regimen. R-miniCHOP...
- Additionally,
ibrutinib down-modulates the
expression of CD20 (target of
rituximab/ofatumumab) by
targeting the CXCR4/SDF1 axis. Together,
these data are...
-
combined today with
rituximab. This
regimen is then
called ICE-R or R-ICE or RICE. [R]-ICE
regimen consists of:[citation needed]
Rituximab - an anti-CD20 monoclonal...
- (MCL), with or
without prior rituximab-containing
chemoimmunotherapy treatment, is
bendamustine with
mitoxantrone and
rituximab. In
Germany in 2012 it has...
